Galactosemia cost-effectiveness of therapy

Galactosemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Galactosemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Galactosemia cost-effectiveness of therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Galactosemia cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Galactosemia cost-effectiveness of therapy
CDC on Galactosemia cost-effectiveness of therapy
Galactosemia cost-effectiveness of therapy in the news
Blogs on Galactosemia cost-effectiveness of therapy
Directions to Hospitals Treating Galactosemia
Risk calculators and risk factors for Galactosemia cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sujaya Chattopadhyay, M.D.[2]

Cost-Effectiveness of Therapy

The screening cost of galactosemia is less than the benefits i.e. QALYs achieved through screening, thereby making its implementation cost-effective. Moreover, decreasing the false-positives, using healthcare information systems and economical diagnostic techniques, establishing a centralized laboratory and combining with other screening programs will help in further reducing the financial burden.